From Ocean City, Maryland, USA:
Upon my visit yesterday to Johns Hopkins Hospital, I discussed with our doctor the theoretical link to cancer with insulin analogs and explained that was my reason for not switching to the Lantus/NovoLog regimen. I have read several studies that discuss a link. She suggested I write to you and ask for more information as I was her only patient that was concerned about this.
In the last few years, very few studies have been published about insulin analogs and their carcinogenic effect. To my knowledge, none of the studies have been about the insulin analogs, both short or long acting ones, currently used in the clinical management of diabetes. On the contrary, many studies have been published about the beneficial effects of the use of the same analogs (most of all about glargine) used in the therapy of kids, teens, and adults, with type 1 diabetes. In my practice, I have many kids using glargine associated both with short acting analogs or rapid insulin and they are in good metabolic control.
|Return to the Top of This Page|
Last Updated: Tuesday April 06, 2010 15:10:04
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.